-ATX-01 is the industry's first anti-microRNA therapeutic to be investigated in DM1 – VALENCIA, Spain, Oct. 18, 2024 /PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression, announced...
ARTHEx Biotech Announces First Patient Dosed in Phase I-IIa ArthemiR™ Trial for Myotonic Dystrophy Type 1 (DM1)
Seaking AlphaSeeking Alpha / Seaking Alpha 7 hours ago 1 Views
Comments